Third-Trimester Prenatal Syphilis Screening
Authors:
- Jenna B. EmersonJEJenna B. Emerson
- Erika F. WernerEWErika F. Werner
- Brenna L. HughesBHBrenna L. Hughes
- 1 September 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 126 (3) , 479-485
Abstract
To estimate the cost to prevent one case of congenital syphilis or fetal or neonatal death with universal third-trimester syphilis rescreening in the United States and to estimate the incidence of syphilis seroconversion at which rescreening becomes cost-effective. We created a decision model comparing universal third-trimester syphilis rescreening in women who screened negative in the first trimester with no rescreening. The assumed base case incidence of seroconversion was 0.012%. The primary outcome was the cost to prevent one case of congenital syphilis. Secondary outcomes included the cost to prevent one fetal or neonatal death and the number needed to rescreen to prevent one adverse outcome. A strategy was considered cost-effective if it cost less than $285,000 to prevent one case of congenital syphilis (the estimated long-term care cost). Under our assumptions, universal third-trimester rescreening would cost an additional $419,842 for each case of congenital syphilis prevented and $3,621,144 and $6,052,534, respectively, for each fetal and neonatal death prevented. Rescreening 4,000,000 women would prevent 60 cases of congenital syphilis and seven fetal and four neonatal deaths. Prevention of one case of congenital syphilis would require 65,790 women be rescreened. Seroconversion incidence of 0.017% would make third-trimester rescreening cost-effective. Universal third-trimester syphilis rescreening requires a large number of women be rescreened at a high health care cost to prevent one adverse outcome from maternal syphilis. Seroconversion incidence must be 19-fold higher than the national average of primary and secondary syphilis in women for universal third-trimester rescreening to be cost-effective.Keywords
This publication has 29 references indexed in Scilit:
- Cost and clinical utility of repeated syphilis screening in the third trimester in a high-risk populationAmerican Journal of Obstetrics and Gynecology, 2014
- The Cost and Cost-Effectiveness of Scaling up Screening and Treatment of Syphilis in Pregnancy: A ModelPLOS ONE, 2014
- Screening for Syphilis Infection in Pregnant Women: Evidence for the U.S. Preventive Services Task Force Reaffirmation Recommendation StatementAnnals of Internal Medicine, 2009
- Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care OrganisationDrug Safety, 2007
- Assessment of the Value of Rescreening for Syphilis in the Third Trimester of PregnancyInfectious Diseases in Obstetrics and Gynecology, 2006
- Treatment of Syphilis in Pregnancy and Prevention of Congenital SyphilisClinical Infectious Diseases, 2002
- Congenital syphilis after maternal treatment for syphilis during pregnancyAmerican Journal of Obstetrics and Gynecology, 2002
- Strategic options for antenatal screening for syphilis in the United Kingdom: a cost effectiveness analysisJournal of Medical Screening, 2000
- Cost‐effectiveness of antenatal screening for syphilisHealth Care for Women International, 1995
- Economic Evaluation of Maternal Screening to Prevent Congenital SyphilisSexually Transmitted Diseases, 1983